Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

GOVERNMENT INSTITUTIONS IN CONTROL OF PROCESS!!! ARE THEY HELPING???

Frustrating that Merck can enroll 1,000 people in 4 weeks and then in our Activ trial which is supposed to accelerate Covid solutions we are at 1/4 the number in 3-4 months time ...

This is possibly the power of having thousands of sales people and partnering w BP ?

Also interesting that Merck unblinded the results ?

Something seems unusual about the Merck trial and circumstances. Plus Merck results are only to 29 days. ~ Equalizer, Y@h00 RLFTF finance conversations ———

EIDD-2801 resembles the chemicals with which replicating viruses build their genes. “When the virus incorporates molecules from the drug into its RNA, there is a lethal accumulation of mistakes — an error catastrophe,” said Prof Ralph Baric, a coronavirus expert at the University of North Carolina who has been working for several years with colleagues at Emory to develop EIDD-2801.

It is in the same class of drug as Gilead Sciences’ remdesivir, the antiviral that has so far shown most promise for treating Covid-19 patients in trials, but they work in a different way, said Roger Perlmutter, Merck’s head of research.

“Remdesivir blocks an enzyme that the virus needs to replicate,” he said. “EIDD-2801 causes the enzyme to make mistakes and these errors lead to a catastrophic mutational burden.”

https://www.ft.com/content/de7df1ee-c566-4c79-9b3e-9b7d792d424c

CAN THE BEST OF VACCINES OR OTHER ANTIVIRAL DRUG, DO THIS???

VIP is known to target the VPAC1 receptor of the alveolar type II (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.

Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and primarily concentrated in the lungs. In addition, VIP has been shown in more than hundreds of peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation says the company.

Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the company.

https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic